Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 261 publications
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
Journal: Journal for immunotherapy of cancer
Published: June 10, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.
Journal: Journal for immunotherapy of cancer
Published: March 31, 2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Journal: Future oncology (London, England)
Published: March 31, 2026
YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 22, 2026
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.
Journal: Journal for immunotherapy of cancer
Published: March 13, 2026
Upadacitinib Achieved Rapid Response in Biologic-Refractory Immune Checkpoint Inhibitor-Related Enterocolitis.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: March 10, 2026
Neoadjuvant Immune Therapy in Patients With Melanoma: Response and Toxicity in a Non-Clinical Trial Setting.
Journal: Journal of surgical oncology
Published: February 18, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data.
Journal: Journal for immunotherapy of cancer
Published: February 10, 2026
Pre-treatment naïve T cells are associated with severe irAE following PD-1/CTLA4 checkpoint blockade for melanoma.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Last Updated: 09/26/2026